{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:50:11Z","timestamp":1795053011215,"version":"4.10.2"},"reference-count":19,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MVA-BN-PRO (BN ImmunoTherapeutics) is a candidate immunotherapy product for the treatment of prostate cancer. It encodes 2 tumor-associated antigens, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP), and is derived from the highly attenuated modified vaccinia Ankara (MVA) virus stock known as MVA-BN. Past work has shown that the immunogenicity of antigens can be improved by targeting their localization to exosomes, which are small, 50- to 100\u2013nm diameter vesicles secreted by most cell types. Exosome targeting is achieved by fusing the antigen to the C1C2 domain of the lactadherin protein. To test whether exosome targeting would improve the immunogenicity of PSA and PAP, 2 additional versions of MVA-BN-PRO were produced, targeting either PSA (MVA-BN-PSA-C1C2) or PAP (MVA-BN-PAP-C1C2) to exosomes, while leaving the second transgene untargeted. Treatment of mice with MVA-BN-PAP-C1C2 led to a striking increase in the immune response against PAP. Anti-PAP antibody titers developed more rapidly and reached levels that were 10- to 100-fold higher than those for mice treated with MVA-BN-PRO. Furthermore, treatment with MVA-BN-PAP-C1C2 increased the frequency of PAP-specific T cells 5-fold compared with mice treated with MVA-BN-PRO. These improvements translated into a greater frequency of tumor rejection in a PAP-expressing solid tumor model. Likewise, treatment with MVA-BN-PSA-C1C2 increased the antigenicity of PSA compared with treatment with MVA-BN-PRO and resulted in a trend of improved antitumor efficacy in a PSA-expressing tumor model. These experiments confirm that targeting antigen localization to exosomes is a viable approach for improving the therapeutic potential of MVA-BN-PRO in humans. Cancer Res; 71(15); 5235\u201344. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-4076","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T22:40:45Z","timestamp":1308004845000},"page":"5235-5244","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy"],"prefix":"10.1158","volume":"71","author":[{"given":"Ryan B.","family":"Rountree","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie J.","family":"Mandl","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Nachtwey","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Dalpozzo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Do","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Schoonmaker","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Brinkmann","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Dirmeier","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Laus","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Delcayre","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Research and Development, BN ImmunoTherapeutics, Mountain View, California; and 2Bavarian Nordic GmbH, Frauenhoferstrasse 13, Martinsried, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,7,28]]},"reference":[{"key":"2022061702564932700_bib1","article-title":"BNIT-PR-001. An open-label, phase I dose escalation trial of MVA-BN\u00ae-PRO in men with androgen-insensitive prostate cancer.","year":"2007"},{"key":"2022061702564932700_bib2","first-page":"159","article-title":"Purification of a human prostate specific antigen","volume":"17","author":"Wang","year":"1979","journal-title":"Invest Urol"},{"key":"2022061702564932700_bib3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061702564932700_bib4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1677\/erc.1.00950","article-title":"Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer","volume":"12","author":"Veeramani","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"2022061702564932700_bib5","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"2022061702564932700_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061702564932700_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bcmd.2005.07.003","article-title":"Exosome display technology: applications to the development of new diagnostics and therapeutics","volume":"35","author":"Delcayre","year":"2005","journal-title":"Blood Cells Mol Dis"},{"key":"2022061702564932700_bib8","first-page":"31","article-title":"Exosomes as novel therapeutic nanodevices","volume":"8","author":"Delcayre","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"2022061702564932700_bib9","first-page":"751","article-title":"Exosome nanovesicles displaying G protein-coupled receptors for drug discovery","volume":"2","author":"Estelles","year":"2007","journal-title":"Int J Nanomedicine"},{"key":"2022061702564932700_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri2567","article-title":"Membrane vesicles as conveyors of immune responses","volume":"9","author":"Thery","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2022061702564932700_bib11","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/0008-5472.CAN-07-3163","article-title":"Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses","volume":"68","author":"Zeelenberg","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702564932700_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ijc.1556","article-title":"Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors","volume":"94","author":"Elzey","year":"2001","journal-title":"Int J Cancer"},{"key":"2022061702564932700_bib13","first-page":"2434","article-title":"Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure","volume":"35","author":"Corbett","year":"1975","journal-title":"Cancer Res"},{"key":"2022061702564932700_bib14","first-page":"77","article-title":"Construction and isolation of recombinant MVA","volume":"269","author":"Staib","year":"2004","journal-title":"Methods Mol Biol"},{"key":"2022061702564932700_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jviromet.2010.07.003","article-title":"A flow cytometry-based immuno-titration assay for rapid and accurate titer determination of modified vaccinia Ankara virus vectors","volume":"169","author":"Li","year":"2010","journal-title":"J Virol Methods"},{"key":"2022061702564932700_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-1759(02)00330-7","article-title":"Production and characterization of clinical grade exosomes derived from dendritic cells","volume":"270","author":"Lamparski","year":"2002","journal-title":"J Immunol Methods"},{"key":"2022061702564932700_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/334255a0","article-title":"Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells","volume":"334","author":"Stevens","year":"1988","journal-title":"Nature"},{"key":"2022061702564932700_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","article-title":"The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice","volume":"212","author":"Martin","year":"1998","journal-title":"J Immunol Methods"},{"key":"2022061702564932700_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/pros.10130","article-title":"Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer","volume":"53","author":"Gulley","year":"2002","journal-title":"Prostate"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/15\/5235\/2655372\/5235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/15\/5235\/2655372\/5235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:57:57Z","timestamp":1655452677000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/15\/5235\/567784\/Exosome-Targeting-of-Tumor-Antigens-Expressed-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,28]]},"references-count":19,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2011,7,28]]},"published-print":{"date-parts":[[2011,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-4076","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22387743","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502011.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502011","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387743.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387740.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22387740","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,28]]}}}